Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

OBJECTIVE: It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility. This study evaluates biosimilar tumor necrosis factor inhibitor (TNFi) utilization across rheumatology practices in the United States and com...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansback, Nick, Curtis, Jeffrey R., Huang, Jie, He, Zeling, Evans, Michael, Johansson, Tracy, Michaud, Kaleb, Schmajuk, Gabriela, Liao, Katherine P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011419/
https://www.ncbi.nlm.nih.gov/pubmed/32043831
http://dx.doi.org/10.1002/acr2.11106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011419/
https://www.ncbi.nlm.nih.gov/pubmed/32043831
http://dx.doi.org/10.1002/acr2.11106

Ejemplares similares